Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aleph influenza vaccine
- Development stage
- Phase 4
- Lead developer
- Dalian Aleph Biomedical
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Aleph influenza vaccine is an inactivated split influenza vaccine used for the prevention of influenza. It is highly purified and egg-based. The vaccine induces immunity by stimulating the production of antibodies against influenza viruses, specifically targeting strains such as H1N1, H3N2, and B. It is designed to provide protection against seasonal influenza by eliciting a hemagglutination inhibition (HI) antibody response, which is considered a surrogate marker for clinical benefit.
- Brand names
- Aleph
- Other names
- Aleph inactivated split influenza vaccine
02
Targets
HA0 (Influenza B virus hemagglutinin)
Beyond the preview
Go deeper on Aleph influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aleph influenza vaccine.